NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001007

Registered date:04/02/2008

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedAsthma
Date of first enrollment2008/03/01
Target sample size50
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)The first 4 weeks are treated with FP/LABA combination drug and Pranlukast. The second 4 weeks are treated with only FP/LABA combination drug. The first 4 weeks are treated with only FP/LABA combination drug. The second 4 weeks are treated with. FP/LABA combination drug and Pranlukast.

Outcome(s)

Primary OutcomePeripheral airway inflammation in induced sputum (Eosinophils, ECP and Eotaxin)
Secondary Outcome1.Asthmatic symptoms and QOL(AQLQ) 2.Pulmonary functions (PEF, FEV1, FEF50, FEF75) 3.Eosinophils in peripheral blood

Key inclusion & exclusion criteria

Age minimum16years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1.Past treatments with anti-LT drugs in the previous 3 months. 2.Past treatments with oral corticosteroids in the previous 2 weeks. 3.Chronic obstructive lung disease(COPD) and other respitatory disease. 4.Severe liver, kidney, heart , hematic and other diseases 5.Inappropriate patients from the doctor's viewpoint.

Related Information

Contact

public contact
Name Hiroyuki Ohbayashi
Address 76-1, Toki-Cho, Mizunami City, Gifu Pref., 509-6101, Japan Japan
Telephone 0572-68-4111
E-mail ohbayasi@nn.iij4u.or.jp
Affiliation JA Tohno Kousei Hospital Allergy and Respiratory Medicine
scientific contact
Name Mitsuru Adachi
Address 1-5-8, Hatanodai, Sinagawa-ku, Tokyo Japan
Telephone 03-3784-8000
E-mail
Affiliation Showa University School of Medicine First Department of Internal Medicine